Answers are grounded in this paper and cite their sources.
Even though both targeted and immunotherapy-based therapies have been established as frontline standard-of-care for patients with advanced lung cancer, adverse events, resistance, and disease progression remain unavoidable in most instances. In this scenario, chemotherapy is a popular salvage option, but it has restricted therapeutic index. Antibody-drug conjugates (ADCs) have emerged as a viable option. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy to deliver cytotoxic payloads to cancer cells in a direct fashion. Among the promising ADCs used in advanced solid tumors, HER2 targeted ADCs of trastuzumab ematansine and trastuzumab deruxtecan are key drugs in this field.
No takes yet. Share an insight, caveat, or question.
Abuhelwa et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: